Antisera, immunoglobulins, monoclonal antibodies, and vaccines — whether for human or veterinary use — are among the most tightly regulated biologics in international trade, subject to FDA Center for Biologics Evaluation and Research (CBER) licensing requirements for human biologics and USDA Center for Veterinary Biologics (CVB) oversight for animal vaccines. Each lot of imported human vaccine or blood fraction typically requires FDA lot release before distribution in the US market, a process that can add weeks to the supply timeline. Cold-chain integrity is a non-negotiable compliance element: temperature excursions during transit can render a shipment inadmissible regardless of documentation status.

AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.